EDGAR Filing Documents for 0001062993-17-002441

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:

SEC Accession No. 0001062993-17-002441

Filing Date

2017-05-12

Accepted

2017-05-12 17:08:48

Documents

Period of Report

2017-05-12

Document Format Files

Seq	Description	Document	Type	Size
1	FORM 6-K	form6k.htm	6-K	5379
2	EXHIBIT 99.1	exhibit99-1.htm	EX-99.1	280578
3	EXHIBIT 99.2	exhibit99-2.htm	EX-99.2	269042
4	EXHIBIT 99.3	exhibit99-3.htm	EX-99.3	7150
5	EXHIBIT 99.4	exhibit99-4.htm	EX-99.4	7138
6	EXHIBIT 99.5	exhibit99-5.htm	EX-99.5	21961
7	GRAPHIC	exhibit99-1x1x1.jpg	GRAPHIC	6435
8	GRAPHIC	exhibit99-2x5x1.jpg	GRAPHIC	23959
9	GRAPHIC	exhibit99-2x6x1.jpg	GRAPHIC	32416
10	GRAPHIC	exhibit99-5x1x1.jpg	GRAPHIC	4757
	Complete submission text file	0001062993-17-002441.txt		685871

Mailing Address 2488 DUNWIN DRIVE MISSISSAUGA A6 L5L 1J9

Business Address 2488 DUNWIN DRIVE MISSISSAUGA A6 L5L 1J9 (416) 595-0627

Trillium Therapeutics Inc. (Filer) CIK: 0001616212 (see all company filings)